Drug Trial Radar · NCT04590053
Allocetra-OTS in COVID-19, Phase II
Last checked: Nov 19, 2026Latest source record: Oct 22, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
24
Planned (sponsor's estimate)
Start
Oct 20, 2020
Primary completion
Feb 2021
Study completion Mar 2021
Sponsor
- Lead sponsor
- Hadassah Medical OrganizationAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Barzilai Medical Center; Tel-Aviv Sourasky Medical Center
- First posted
- Oct 19, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, open-label study evaluating the safety of Allocetra-OTS, in up to 24 subjects with severe COVID-19 and respiratory dysfunction. Subjects, who will be identified as suffering from COVID-19, will be recruited. After signing an informed consent by the patient and, within 24+6 hours following the time of eligibility (time 0), on Day 1, eligible recipient subjects will receive single intravenous (IV) administration of investigational product as described below. Subjects will be hospitalized for COVID-19, and later as medically indicated. Following the investigational product (IP) administration (Day 1), subjects will be followed for efficacy and safety assessments through 28 days.
Conditions
- Covid19
Interventions
Allocetra-OTSBiological
Allocetra-OTS is a cell-based therapeutic composed of donor early apoptotic cells, comprising allogeneic mononuclear enriched cell suspension with at least 40% early apoptotic cells. The suspension is prepared with Ringer's lactate solution and administered IV. It is stored at 2-8°C until 20+25 minutes before infusion and at room temperature thereafter. Each dose contains 140x10E6 ± 20% cells/ kg of recipient body weight (at screening) in a total volume of 375 mL in a transfer pack that undergoes irradiation and is administered via an adjusted filter using a volumetric pump, at a starting rate of 48 mL/hour with a gradual increase every 15-25 minutes of 15 mL/hour to a maximal rate of 102 mL/hour. The study intervention should be completed within 72 hours of completing the manufacturing process. During product administration, no other IV fluids such as Ringer's lactate or normal saline will be given in parallel unless medically indicated due to volume depletion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of safety by determining the number of participants with any Adverse Events (AE) and Serious Adverse Events (SAE)Time frame: 28 days follow up
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Barzilai Medical Center
Ashkelon, Israel · Not yet recruiting
Hadassah Medical Center
Jerusalem, Israel · Recruiting
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.